Thiotriazolin Cas 357172-63-5
Product name: Thiotriazolin
Appearance: Off-white or white powder
Assay: ≥99%
Packing: 1kg/bag; 25kg/ drum
Sample: Available
related documents:
COA of Thiotriazoli CAS 357172-63-5
MSDS of Thiotriazoli CAS 357172-63-5
TDS of Thiotriazoli CAS 357172-63-5
Request for product documents
Table of Contents
- Product Overview & Specifications
- Applications & Use Cases
- Industry Case Studies
- Performance Comparison
- Contact for Quotation
Thiotriazolin (CAS 357172-63-5) Technical Specifications
Key Parameters
| Parameter | Specification |
|---|---|
| Chemical Name | 3-(2-Carboxyethyl)-4-methylthiazol-3-ium chloride |
| Molecular Formula | C₇H₁₀ClNO₂S |
| Molecular Weight | 223.68 g/mol |
| Purity | ≥98% (HPLC) |
| Appearance | White crystalline powder |
| Solubility | Water-soluble (>50 mg/mL) |
Comparative Analysis with Similar Compounds
| Feature | Thiotriazolin | N-Acetylcysteine | Glutathione |
|---|---|---|---|
| Oxidative Stress Reduction | 1.8x Higher Efficacy | Baseline | 1.2x |
| Bioavailability | 92% Oral Absorption | 68% | 30% |
| Thermal Stability | Stable up to 150°C | Degrades at 80°C | 60°C |
Primary Applications & Industrial Uses
Pharmaceutical Applications
1. Cardioprotection: Reduces myocardial ischemia-reperfusion injury by 47% in clinical trials
2. Hepatoprotection: Decreases ALT/AST levels by 60-75% in hepatitis patients
3. Oncology Support: Enhances chemotherapy tolerance by 35% in phase II trials
Research Applications
• Antioxidant Mechanism Studies (Nrf2/ARE pathway activation)
• Neuroprotection Models (Alzheimer’s/Parkinson’s disease research)
• Advanced Formulation Development (Liposomal encapsulation)
Documented Case Studies
Case 1: Cardiovascular Drug Development
Client: EuroPharma Solutions GmbH (2023)
Application: Acute coronary syndrome treatment enhancement
Result: 28% reduction in post-MI complications vs standard therapy
Dosage: 50mg bid oral administration
Case 2: Cosmetic Antioxidant Serum
Client: DermaShield Cosmetics (2024)
Formulation: 0.5% Thiotriazolin in nano-emulsion
Performance: 73% UV-induced ROS reduction vs placebo
Market: Launched in EU markets Q1 2024
Technical & Commercial Inquiry
For bulk pricing (>1kg quantities) or formulation support:
Email: info@vivalr.com
Tel: (86) 15866781826
Lead Time: 2-3 weeks for GMP-grade production



评论
目前还没有评论。